Upstream Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Upstream Bio (Nasdaq: UPB), a clinical-stage company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO, Rand Sutherland, MD, MPH, will deliver a presentation on Monday, January 13, 2025, at 2:15 p.m. PT.
The presentation will be accessible via live webcast through the 'Events' tab on the 'Investors' section of Upstream Bio's website. For those unable to attend the live session, a replay will be made available on the company's website following the presentation.
Upstream Bio (Nasdaq: UPB), un'azienda in fase clinica focalizzata nello sviluppo di trattamenti per malattie infiammatorie, in particolare disturbi respiratori gravi, ha annunciato la sua partecipazione al 43° Congresso Annuale J.P. Morgan Healthcare. Il CEO dell'azienda, Rand Sutherland, MD, MPH, presenterà un intervento lunedì 13 gennaio 2025, alle 14:15 PT.
La presentazione sarà accessibile tramite webcast dal vivo nella sezione 'Eventi' della pagina 'Investitori' del sito web di Upstream Bio. Per coloro che non possono partecipare alla sessione dal vivo, sarà disponibile una registrazione sul sito dell'azienda dopo la presentazione.
Upstream Bio (Nasdaq: UPB), una empresa en etapa clínica centrada en el desarrollo de tratamientos para enfermedades inflamatorias, especialmente trastornos respiratorios severos, ha anunciado su participación en la 43ª Conferencia Anual de Salud J.P. Morgan. El CEO de la empresa, Rand Sutherland, MD, MPH, realizará una presentación el lunes 13 de enero de 2025, a las 2:15 p.m. PT.
La presentación será accesible a través de una transmisión web en vivo en la pestaña 'Eventos' de la sección 'Inversores' del sitio web de Upstream Bio. Para aquellos que no puedan asistir a la sesión en vivo, se pondrá a disposición una repetición en el sitio web de la empresa después de la presentación.
Upstream Bio (Nasdaq: UPB), 염증성 질환, 특히 중증 호흡기 질환 치료제 개발에 집중하는 임상 단계 회사가 제43회 J.P. 모건 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 CEO인 Rand Sutherland, MD, MPH는 2025년 1월 13일 월요일, 오후 2:15 PT에 발표를 진행할 예정입니다.
발표는 Upstream Bio 웹사이트의 '투자자' 섹션의 '이벤트' 탭을 통해 실시간 웹캐스트로 접근할 수 있습니다. 실시간 세션에 참석할 수 없는 분들을 위해 회사 웹사이트에 발표 후 다시 보기를 제공할 예정입니다.
Upstream Bio (Nasdaq: UPB), une entreprise en phase clinique axée sur le développement de traitements pour les maladies inflammatoires, en particulier les troubles respiratoires sévères, a annoncé sa participation à la 43e Conférence Annuelle de J.P. Morgan Healthcare. Le PDG de l'entreprise, Rand Sutherland, MD, MPH, fera une présentation le lundi 13 janvier 2025, à 14h15 PT.
La présentation sera accessible via un webinaire en direct dans l'onglet 'Événements' de la section 'Investisseurs' du site Web d'Upstream Bio. Pour ceux qui ne peuvent pas assister à la session en direct, un replay sera disponible sur le site de l'entreprise après la présentation.
Upstream Bio (Nasdaq: UPB), ein klinisches Unternehmen, das sich auf die Entwicklung von Behandlungen für entzündliche Krankheiten, insbesondere schwerwiegende Atemwegserkrankungen, konzentriert, hat seine Teilnahme an der 43. J.P. Morgan Healthcare Conference bekannt gegeben. Der CEO des Unternehmens, Rand Sutherland, MD, MPH, wird am Montag, den 13. Januar 2025, um 14:15 Uhr PT eine Präsentation halten.
Die Präsentation wird über einen Live-Webcast über den Reiter 'Events' im Bereich 'Investoren' auf der Website von Upstream Bio zugänglich sein. Für diejenigen, die nicht an der Live-Session teilnehmen können, wird eine Wiederholung nach der Präsentation auf der Website des Unternehmens verfügbar sein.
- None.
- None.
WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, MPH, Upstream Bio’s CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 2:15 p.m. PT.
A live webcast of the presentation will be available under the “Events” tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be posted on the Company's website following the presentation.
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.
FAQ
When is Upstream Bio (UPB) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Upstream Bio's (UPB) J.P. Morgan Healthcare Conference presentation?
Will there be a replay available of Upstream Bio's (UPB) J.P. Morgan presentation?
What is Upstream Bio's (UPB) current focus in drug development?
